BioCentury | Dec 7, 2019
Clinical News

Bladder cancer data poise FerGene gene therapy to compete with Keytruda

...CR rate of 18% in a clinical trial. Data from the nadofaragene trial, conducted by FKD Therapies Oy...
...will assume exclusive, worldwide rights to the compound from FKD upon approval of a BLA. FKD...
BioCentury | Nov 25, 2019
Company News

Blackstone places $400M bet to launch Ferring gene therapy subsidiary

...FKD Therapies Oy last year for an undisclosed sum. Nadofaragene originated from Merck & Co. Inc. (NYSE:MRK); FKD...
...high levels of the naturally occurring antitumor protein. Elizabeth S. Eaton, Staff Writer Blackstone Life Sciences Ferring Pharmaceuticals A/S FKD Therapies Oy interferon...
BioCentury | May 4, 2018
Company News

Ferring gains option for bladder cancer gene therapy

...Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi. FKD...
...BCG therapy. FKD Therapies Oy, Kuopio, Finland Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Cancer Jennie Walters Instiladrin, rAd-IFN Ferring Pharmaceuticals A/S FKD Therapies Oy...
BioCentury | May 3, 2018
Company News

Ferring gains option for bladder cancer gene therapy

...Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi. FKD...
...Fast Track designations to treat NMIBC in patients unresponsive to BCG therapy. Jennie Walters Instiladrin, rAd-IFN Ferring Pharmaceuticals A/S FKD Therapies Oy Interferon Merck...
BioCentury | Sep 26, 2011
Company News

FKD, Merck deal

...Merck granted newco FKD exclusive rights to a gene therapy cancer candidate in exchange for an...
...to a gene therapy cancer candidate in exchange for an equity stake. Founded in February, FKD...
...The newco plans to begin Phase II testing in superficial bladder cancer next half. FKD...
BioCentury | Sep 21, 2011
Company News

Merck, Finnish newco in gene therapy deal

...Merck & Co. Inc (NYSE:MRK) granted newco FKD Therapies Oy (Kuopio, Finland) exclusive rights to a gene therapy...
...to a gene therapy cancer candidate in exchange for an equity stake. Founded in February, FKD...
...rAd-IFN). The newco plans to begin Phase II testing in superficial bladder cancer next half. FKD...
Items per page:
1 - 6 of 6
BioCentury | Dec 7, 2019
Clinical News

Bladder cancer data poise FerGene gene therapy to compete with Keytruda

...CR rate of 18% in a clinical trial. Data from the nadofaragene trial, conducted by FKD Therapies Oy...
...will assume exclusive, worldwide rights to the compound from FKD upon approval of a BLA. FKD...
BioCentury | Nov 25, 2019
Company News

Blackstone places $400M bet to launch Ferring gene therapy subsidiary

...FKD Therapies Oy last year for an undisclosed sum. Nadofaragene originated from Merck & Co. Inc. (NYSE:MRK); FKD...
...high levels of the naturally occurring antitumor protein. Elizabeth S. Eaton, Staff Writer Blackstone Life Sciences Ferring Pharmaceuticals A/S FKD Therapies Oy interferon...
BioCentury | May 4, 2018
Company News

Ferring gains option for bladder cancer gene therapy

...Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi. FKD...
...BCG therapy. FKD Therapies Oy, Kuopio, Finland Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Cancer Jennie Walters Instiladrin, rAd-IFN Ferring Pharmaceuticals A/S FKD Therapies Oy...
BioCentury | May 3, 2018
Company News

Ferring gains option for bladder cancer gene therapy

...Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi. FKD...
...Fast Track designations to treat NMIBC in patients unresponsive to BCG therapy. Jennie Walters Instiladrin, rAd-IFN Ferring Pharmaceuticals A/S FKD Therapies Oy Interferon Merck...
BioCentury | Sep 26, 2011
Company News

FKD, Merck deal

...Merck granted newco FKD exclusive rights to a gene therapy cancer candidate in exchange for an...
...to a gene therapy cancer candidate in exchange for an equity stake. Founded in February, FKD...
...The newco plans to begin Phase II testing in superficial bladder cancer next half. FKD...
BioCentury | Sep 21, 2011
Company News

Merck, Finnish newco in gene therapy deal

...Merck & Co. Inc (NYSE:MRK) granted newco FKD Therapies Oy (Kuopio, Finland) exclusive rights to a gene therapy...
...to a gene therapy cancer candidate in exchange for an equity stake. Founded in February, FKD...
...rAd-IFN). The newco plans to begin Phase II testing in superficial bladder cancer next half. FKD...
Items per page:
1 - 6 of 6